Open-label, phase I/randomized, phase II trial of the triple angiokinase inhibitor, nintedanib, versus sorafenib in previously untreated patients with advanced hepatocellular carcinoma (HCC).
Daniel H. Palmer
Consultant or Advisory Role - Boehringer Ingelheim (U)
Research Funding - Boehringer Ingelheim
Markus Peck-Radosavljevic
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim
Research Funding - Boehringer Ingelheim
Yuk Ting Ma
No relevant relationships to disclose
Janet Graham
No relevant relationships to disclose
Laetitia Fartoux
No relevant relationships to disclose
Richard Hubner
Consultant or Advisory Role - Novartis
Arsene Bienvenu Loembe
Employment or Leadership Position - Boehringer Ingelheim
Matus Studeny
Employment or Leadership Position - Boehringer Ingelheim
Julia Hocke
Employment or Leadership Position - Boehringer Ingelheim
Tim Meyer
No relevant relationships to disclose